Leone J, et al. - Researchers studied 1,187 male breast cancer (MBC) and 166,054 female breast cancer (FBC) cases with known hormone receptor (HR) status and human epidermal growth factor receptor 2 (HER2) between 2010 and 2013 to assess the differences in overall survival (OS) between MBC and FBC according to tumor subtype. They noted OS rates of 85.6% and 90.4% 3 years for MBC and FBC, respectively. They observed that MBC was often HR+/HER2−, more ductal, had a higher grade, and presented with more advanced stage. They noticed a worse OS in MBC vs FBC in stages I and II, but equivalent OS in stages III and IV. They found that HR+/HER2+ was the only subtype with significant differences in OS between MBC and FBC upon multivariate analysis.